Profil
Paul F.
Howley worked as a Research Director at Bavarian Nordic A from 1998 to 2002.
He then worked as a Technical Director at Prescient Therapeutics Ltd.
from 2002 to 2008.
After that, he worked as a Director of Virology & Protein Chemistry at Sentinext Therapeutics Sdn.
Bhd.
Dr. Howley received his undergraduate degree from The University of Reading in 1985.
Ehemalige bekannte Positionen von Paul F. Howley
| Unternehmen | Position | Ende |
|---|---|---|
| PRESCIENT THERAPEUTICS LIMITED | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2008 |
| BAVARIAN NORDIC A/S | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2002 |
Sentinext Therapeutics Sdn. Bhd.
 Sentinext Therapeutics Sdn. Bhd. BiotechnologyHealth Technology Sentinext Therapeutics Sdn. Bhd. develops vaccines and therapeutics for tropical infectious diseases. Its pharmaceutical research and development focuses on EV71, polio, influenza and dengue diseases. The company was founded by Mary Jane Cardosa and Peter Samuel Wulff in 2009 and is headquartered in Penang, Malaysia. | Corporate Officer/Principal | - |
Ausbildung von Paul F. Howley
| The University of Reading | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BAVARIAN NORDIC A/S | Health Technology |
| PRESCIENT THERAPEUTICS LIMITED | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Sentinext Therapeutics Sdn. Bhd.
Sentinext Therapeutics Sdn. Bhd. BiotechnologyHealth Technology Sentinext Therapeutics Sdn. Bhd. develops vaccines and therapeutics for tropical infectious diseases. Its pharmaceutical research and development focuses on EV71, polio, influenza and dengue diseases. The company was founded by Mary Jane Cardosa and Peter Samuel Wulff in 2009 and is headquartered in Penang, Malaysia. | Health Technology |
